Navigation Links
High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study

CHARLOTTE, N.C., Sept. 11 /PRNewswire/ -- In a new study, men with locally recurrent prostate cancer may be able to receive a promising investigational ultrasound treatment option.

A Phase III clinical trial at Specialists in Urology, located in North Naples, FL, is investigating the safety and efficacy of High Intensity Focused Ultrasound (HIFU) for the treatment of locally recurrent prostate cancer following failed external beam radiation therapy (EBRT). HIFU is a minimally invasive procedure that uses ultrasound energy to destroy cancerous tissue with focused sound waves.

The lead investigator of this trial site is Dr. Nicholas Franco. This is one of several trial sites in the nation approved by the Food and Drug Administration to participate in the trial, which will begin enrolling patients in September.

HIFU is intended to eliminate cancer by elevating tissue temperatures to more than 195 degrees Fahrenheit in a matter of seconds. The Sonablate(R) 500, the therapeutic ultrasound device, which will be used in the study, is designed to destroy the entire gland in one procedure without causing damage to tissue around the prostate.

Eligible participants for the trial must be between the ages of 40 and 80, have biopsy confirmed local recurrence two or more years following EBRT, confined prostate cancer with a prostate specific antigen (PSA) greater than or equal to .5 ng/mL and less than or equal to 10 ng/mL and a Gleason score of less than or equal to seven.

For more information about enrolling in the HIFU trial, call 1-877-874-4389, or visit

This investigational treatment is performed on an outpatient basis. Potential risks of the treatment include frequency, urgency, mild discomfort or discharge in urinary stream. Less common side effects may also include urinary stricture, retention, incontinence, impotence and rectal fistula.

Prostate cancer is the most common type of non-skin cancer in American men and the second leading cause of cancer deaths in men. The American Cancer Society estimates that there were about 234,460 new cases of prostate cancer in the U.S. in 2006 and that 27,350 men die annually from the disease.

Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Nations Foremost Health Care Leaders Kick Off Summit Focused on Zero-Tolerance Approach to Hospital-Acquired Infections
2. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
3. ACORNs Oncology-focused Contract Research Organization Exceeds Projections
4. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
5. Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
6. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
7. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
8. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
9. Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
10. Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease
11. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
Post Your Comments:
(Date:11/24/2015)... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . --> ... Diabetes Mellitus (T1DM), will be a key driver of market growth to ... The uptake of recently approved and pipeline premium products for Type ... to 2021, says GBI Research . ...
(Date:11/24/2015)... PAUL, Minn. , Nov. 24, 2015  Enova ... with Novocam of Helsinki, Finland ... Both companies are at the cutting edge of medical ... Headlights in the United States ... dental cameras. Together, they provide the world,s most powerful ...
(Date:11/24/2015)...  BioPlast Manufacturing, a manufacturer of plastic components ... and biotech environments, announced today that it has ... dishes. This acquisition is aligned with BioPlast Manufacturing,s ... that are designed and tested by scientists for ... Bristol, Pennsylvania injection ...
Breaking Medicine Technology:
(Date:11/24/2015)... , ... November 24, 2015 , ... Autism Speaks, the ... global movement driven by social media and the generosity of people around the world. ... their social media networks to give – and share the personal stories behind those ...
(Date:11/24/2015)... ... 24, 2015 , ... World Patent Marketing , a ... invention that revolutionizes the vending machine industry by providing healthy and fresh smoothies ... billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Shakes ...
(Date:11/24/2015)... Nashville, Tennessee (PRWEB) , ... November 24, 2015 , ... ... 2015-2016 Pharmacy Quality Trend Report . Throughout the past year there have been multiple ... more mature state. During this transition, PharmMD has enabled their customers and partners to ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Dehydration, defined ... much body water to perspiration in the hot sun, and heat stroke and death ... water advocate and radio host Sharon Kleyne. Every cell, system and structure requires water ...
(Date:11/24/2015)... ... November 24, 2015 , ... “I am so thrilled, as a newbie here, to leave a ... won a $7,500 School Lounge Makeover® from California Casualty . Stephanie is in her ... has a much longer tenure. , “This is such an amazing school and we deserve ...
Breaking Medicine News(10 mins):